MedTrace Logo

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

NCT00019006 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-03-04

No results posted yet for this study

Summary

RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.

Conditions

  • Recurrent Colon Cancer
  • Extensive Stage Small Cell Lung Cancer
  • Stage III Pancreatic Cancer
  • Stage III Rectal Cancer
  • Limited Stage Small Cell Lung Cancer
  • Recurrent Pancreatic Cancer
  • Recurrent Rectal Cancer
  • Stage III Non-small Cell Lung Cancer
  • Stage I Pancreatic Cancer
  • Stage II Non-small Cell Lung Cancer
  • Stage IVB Pancreatic Cancer
  • Stage II Pancreatic Cancer
  • Stage III Colon Cancer
  • Stage IVA Pancreatic Cancer

Interventions

DRUG

Detox-B adjuvant

DRUG

ras peptide cancer vaccine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Samir N. Khleif · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00019006 on ClinicalTrials.gov